Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by FredTheVoiceon Apr 20, 2018 11:52am
158 Views
Post# 27917743

Coming up.....

Coming up.....What if the only thing pulling a little bit the stock to surge was anticipation of the market that a bought deal is coming up. Why ? A bought deal at 10$ a share soon enough to upward the money in the bank, to finance the buying of one or two drugs, like TANGUAY was talking about recently.

He advance that he wants his employees to have more drugs to sell, to offer.

After that, all the goods news are coming up, and relatively sooner than later: 1. infos about Europe approval process; first indication for TROGARZO sales; first profits declared at quarter 2018- 2, ...

I'm impressed that the market hesitates to give TH a better value at the moment. But time is on our side. And the big boys will have their pants on the ground if they dont take rapidly a good position in TH. Because the facts are strong: Trogarzo appproved; good price; great label; seems that the launch is well started........and a team of directors and sales people very competent.

12$ for the stock at the end of this year like someone mentionned here ? A lot will be dreaming than that they have bought at that price.......but it we be to late.

FTV.
Bullboard Posts